West Pharmaceutical Services (WST) EBIAT (2009 - 2026)

West Pharmaceutical Services' EBIAT history runs 18 years deep, the most recent figure standing at $138.8 million for Q1 2026.

• In Q1 2026, EBIAT rose 54.57% year-over-year to $138.8 million; the TTM figure through Mar 2026 stood at $542.7 million (up 16.16% YoY), while the FY2025 annual figure was $493.7 million, changed 0.2% from the prior year.
• EBIAT came in at $138.8 million for Q1 2026 at West Pharmaceutical Services, up from $132.1 million in the prior quarter.
• In the past five years, EBIAT ranged from a high of $188.5 million in Q2 2022 to a low of $89.8 million in Q1 2025.
• A 5-year average of $135.6 million and a median of $136.0 million in 2024 frame the typical range for EBIAT.
• Across the five-year window, EBIAT plunged 31.32% in 2022 and surged 54.57% in 2026, its largest moves.
• West Pharmaceutical Services' EBIAT stood at $103.0 million in 2022, then surged by 33.01% to $137.0 million in 2023, then slipped by 5.04% to $130.1 million in 2024, then grew by 1.54% to $132.1 million in 2025, then increased by 5.07% to $138.8 million in 2026.
• According to Business Quant data, EBIAT over the past three periods registered $138.8 million, $132.1 million, and $140.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison